• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    An abstract of camomile plant material is stabilised as an inclusion complex with cyclodextrin. The complex can be formulated into pharmaceutical and cosmetic compositions or into animal feeds. The material complexed may be obtained from Flores chamomillae and/or Anthemis nobilis and/or Achillea collina. More specifically the complexed material may be "blue-oil" or aroma and/or flavour extracted from camomile plant material.
    公开号:SU1514240A3
    申请号:SU792849102
    申请日:1979-11-19
    公开日:1989-10-07
    发明作者:Jozhef Sejtli；Lajosh Sente；Derd Kermetsi；Peter Teteni；Agoshton David；Tibor Zilani；Andrash Kelemen；Yanosh Kharshkhedi
    申请人:Khinoin Dedser Esh Vedesete Te；
    IPC主号:
    专利说明:

    The invention relates to biology and can be used in the manufacture of preparations containing cyclodec string chamomile inclusion complexes.
    The purpose of the invention is to increase the stability of the target product.
    Example 1. 10, Og β-cyclodextrin (moisture content of 14.46Ζ) is dissolved in 180 ml of 30Ζ-ηογο ethanolic solution of water at 50 ° C with constant stirring. A solution of 1 g of chamomile oil in ten-fold diluted ethanol is added dropwise to the solution of C-cyclodextrin. After 4-3 minutes after the addition, the mixture becomes cloudy and a crystalline adduct begins to precipitate. Then after 4.5-5 hours, the mixture is slowly cooled to room temperature. Stirring is stopped and the complex is held for
    16 h in the refrigerator. The mixture is filtered through a glass filter and dried over phosphorus pentoxide at room temperature. Obtain 10.06 g of a crystal complex of chamomile oil with / C-cyclo dextrin.
    The content of the active principle in the complex is 8.12 and the yield per chamomile oil is 75.04 Ζ. The efficiency of complexation can be enhanced by using a mixer with a large number of revolutions.
    The empirical formula and molecular weight can be given only in respect of / z-cyclodextrin (4 H, O ° F m 'k' 'col · 1135.0. The average molecular weight of sesquiterpene derivatives chamomile oil is about 230, the average MO a peculiar 1 weight of the complex with the content -
    3,151
    I eat about 77 water approximately! 460.
    Obtained according to example 1, the product is a light blue microcrystalline powder with a faint smell of chamomile. The product does not have a melting point, but it begins to decompose at approximately 200 ° C, this temperature is characteristic of the decomposition of p-cyclodextrins.
    Solubility in distilled water is 0.030-0.035 g / 100 mp; -in 96% ethanol - 0.030 g / 100 ml only oil dissolves in benzene and chloroform, p> -cyclodextrin is practically insoluble in these solvents. (These data refer to a temperature of 25 ° C).
    Aqueous solutions of complexes are always slightly opalescent.
    The complex is stable at room temperature and can be stored without decomposition for at least five months.
    The stability of the product according to example 1 with respect to oxidation is shown in table. one.
    From tab. 1 it follows that the absorption of oxygen by the complex compared to the absorption of oxygen by pure chamomile oil can be neglected.
    When regimen is taken, neither chamomile oil nor cyclodextrin is toxic. These two components do not form a covalent bond and the complex dissociates under physiological conditions.
    Proof of activity by examining the action of the reticulo-endotalial system. The functioning of phagocytes of the reticulo-endothelial system causes histamine, which is a chemical activator. Histamine makes possible the transition of peripheral capillary endothelial cells of veins in a short time into phagocytes, which accumulate in their body the injected dye similar to the cells of the reticulo-endothelial system of the liver, spleen or bone marrow.
    Since chamomile also releases histamine and activates the reticulo-endothelial system, the effectiveness of pure chamomile oil and the inclusion complex can be compared in the sequence of the removal of the dye injected into the bloodstream.
    4240 4
    E as experimental animals were used male GHRP mice with a body weight of 25 ^ 2 g (SGHR means an international strain possessing this genetic information). 0.5 ml of a 107% solution of the dye (25 g body weight) in physiological saline was injected into the tail vein. In that
    17 gelatin was added to stabilize the colloidal system. A suspension containing carbon particles with a diameter of not more than 0.2–1p was used, because a solution with large particles caused a blockage of the pulmonary veins and the animals died from embolism. Before injection of the dye, mice were subcutaneously injected twice with 0.5 ml of physiological saline 20 Pa salt. Animals were given 1 hour before the injection of the dye to reg 5 mg of chamomile oil or 5 MP containing the product described in Example 1. Isolation of the dye
    25 controlled photometrically.
    After intravenous administration of the dye, for all five minutes, 10 ml of blood was sucked into the measuring pipette; the blood was homogenized.
    30 in weakly alkaline water, after which the absorption of light by the solution was determined photometrically.
    The sequence of the selection of the dye from the blood of control animals
    $ 3 and. Animals, which was administered the appropriate drug is given in Table. 2
    The introduction of the dye increased blood extraction by an average of 257. Tab40 personal data show a decrease of this value in groups of 8 animals (on average).
    Toxicity studies of p-cyclodextrin-chamomile complexes
    45 inclusions show that the complex is non-toxic.
    10 female mice (body weight 20–25 g) were obtained in the form of a suspension of chamomile regulative complex in an amount of up to 3000 mg / kg body weight (corresponding to 234 mg of active ingredient / kg body weight), as well as 10 male ml (body weight 20–20 kg). 25 g) received under the same conditions a complex in the amount of up to
    55 3000 mg / kg body weight (corresponds to
    264 mg active / kg
    body). No toxic effects were observed, 10 females and 10
    male rats (body weight 150-200 g) po1514240
    6
    5,000 mg of the chamomile complex per kg of body weight (corresponding to
    430 mg of active principle / kg of body weight
    body), in this case also not observable,
    • about
    given a toxic effect.
    Example 2. Getting kompleh.a include flavoring compounds of chamomile and p-piclodextrin.
    10 g of p> -cyclodextrin was dissolved (θ in 70% by volume aqueous ethanol at 50 ° C, after which 2.5 g of chamomile aromatic compounds obtained from 30 g of chamomile flowers were added as a solution in 10 ml of ethyl alcohol. 15 After 10-12 minutes after the addition, the system becomes turbid, after which the heating is stopped and the reaction mixture is cooled for 4 hours with constant stirring to room temperature.
    temperature The mixture is kept for 16 hours in a refrigerator, filtered through a glass filter and dried over pentoxide phosphorus. 10.8 g of a yellow-white crystalline product are obtained which contain approximately 12% by weight of active principle.
    To obtain a complex containing aromatic and fragrant substances of chamomile flowers, Roman chamomile extract is preferably used (Apieppv ηοΦϋΐβ), since it only slightly contains the components characteristic of the filtered paraffin distillate, and is mainly a source of flavoring and fragrant substances.
    reactions
    Saturated warm water-eta-1 zero cyclodext-solution | +
    Rina>
    warm ethanolic solution of chamomile oil or chamomile extract
    (mixing)
    warm water-ethanol solution of inclusion complexes
    crystals of cyclodextrin-chamomile + mother liquor
    "cyclodextrin-chamomile
    (cooling)
    of the inclusion complex +
    (separation)
    crystals of cyclodextrin and mashrack inclusions (target product)
    removable mother liquor
    Table 1
    Time h Oxygen absorption, ml / mg Chamomile oil 5> -Ci Claude Chrome Mask Complex 70 6 2 80 14 four 120 18 five 160 23 7 200 thirty 7 240 58 7 280 80 7 320 100 7
    eight
    7
    1514240
    table 2
    The period of time after injection of the dye Е С 1 ”Εϋ5 —————— · * - to Е 0 100 Control Chamomile oil The product according to example 1 Between 10-20 min 2.63 7.78 6.75 Between 20-30 min 3.43 3.30 5.60 Between 30-40 min 1.69 5.47 4.67 Only between 10-40 minutes 8.15 16.55 17,12
    Note. The exact value of the extinction at time 0 cannot be determined.
    Εί is the extinction value measured at the time point * after injection of the dye.
    E is the extinction value measured before injection of the dye.
    权利要求:
    Claims (1)
    [1]
    METHOD FOR OBTAINING STABLE CYCLODEXTRIN-ROMADISH COMPLEXES, inclusions, characterized in that, in order to increase the stability of the target product, they mix the water-ethanol solution of p-cyclodextrin with an ethanol content of 30Ζ with an ethanol solution of chamomile oil or chamomile extract at 50 ° C, and the resulting mixture of the ethanol solution of chamomile oil or chamomile extract at 50 ° C, the resulting extract of the ethanol 30Ζ with chamomile oil or chamomile extract at 50 ° C. stirring to room temperature, after which it is kept without stirring and the precipitated crystals of the cyclodextrin-chamomile inclusion complex are separated and dried,
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1514240A3|1989-10-07|Method of producing stable cyclodextrin-pyrethrum complexes
    KR0136722B1|1998-04-25|New compositions containing taxane derivatives
    DE60209145T2|2006-10-26|PHARMACEUTICAL FORMULATIONS WITH PLATIN DERIVATIVES
    KR20010079627A|2001-08-22|Water soluble prodrugs of hindered alcohols or phenols
    EA022890B1|2016-03-31|Injectable melphalan compositions comprising a cyclodextrin derivative and methods of using the same
    NZ211789A|1988-05-30|Pharmaceutical compositions containing an iron | complex of a pyrone derivative, the compositions being adapted for buccal or nasal administration
    DE2710327C3|1981-02-12|Use of benzaldehyde
    EP1529784A1|2005-05-11|Polymeric anhydride of magnesium and proteic ammonium phospholinoleate-palmitoleate.
    US4157391A|1979-06-05|Cholesterol derivative-based medicaments acting on bio-protective mechanisms
    NL8102362A|1981-12-16|PHARMACEUTICAL ANTITUMOR PREPARATION; METHOD FOR THE PREPARATION THEREOF
    FR2584405A1|1987-01-09|FUROSEMIDE SALTS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND PROCESS FOR THEIR PREPARATION
    US4696814A|1987-09-29|Parenteral phenytoin compositions
    RU2313346C2|2007-12-27|Pharmaceutical composition
    FI90824C|1994-04-11|Process for the preparation of lyophilized pharmaceutical phenylquinolinecarboxylic acid compositions
    RU2678772C2|2019-02-01|Cabazitaxel composition
    US4698361A|1987-10-06|Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
    BE1001704A3|1990-02-13|Aqueous compositions containing acid derivative piperidinylcyclopentylheptenoique.
    DE60122384T2|2007-08-16|PROCESS FOR PREPARING A STABLE PHARMACEUTICAL FORM OF PACLITAXEL
    US4089968A|1978-05-16|Stable solutions of ipronidazole
    US20060093628A1|2006-05-04|Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride immonomodulator, its production process and formulation
    RU2181051C1|2002-04-10|Method to obtain injection preparation based upon a substance of p-vitamin activity
    KR0159540B1|1998-12-01|The salt of quinolone carboxylic acid and their pharmaceutical composition containing them
    JP4130700B2|2008-08-06|Antitumor agent-containing composition
    US4322424A|1982-03-30|Crystalline glucoconate salt of m-AMSA and compositions containing same
    CN111939118A|2020-11-17|Pharmacosome for treating hyperthyroidism in response to GSH concentration and preparation method
    同族专利:
    公开号 | 公开日
    HU176217B|1981-01-28|
    AT363176B|1981-07-10|
    NL7908354A|1980-05-22|
    GB2037306B|1983-06-15|
    GB2037306A|1980-07-09|
    PL219739A1|1980-12-01|
    BE880155A|1980-03-17|
    IT1119944B|1986-03-19|
    PL126984B1|1983-09-30|
    FI68174B|1985-04-30|
    DK491679A|1980-05-21|
    FR2441389A1|1980-06-13|
    ES486109A1|1980-09-01|
    JPS5573617A|1980-06-03|
    IT7969222D0|1979-11-16|
    FR2441389B1|1984-02-10|
    NO155625B|1987-01-19|
    ATA738579A|1980-12-15|
    YU280379A|1984-12-31|
    NO793731L|1980-05-21|
    FI68174C|1985-08-12|
    SE7909505L|1980-05-21|
    FI793504A|1980-05-21|
    CH647534A5|1985-01-31|
    DE2944350A1|1980-05-29|
    CS223972B2|1983-11-25|
    DD146893A1|1981-03-11|
    NO155625C|1987-04-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    JPS5443570B2|1972-10-27|1979-12-20|
    JPS5423966B2|1972-11-11|1979-08-17|
    JPS5017529B2|1972-11-20|1975-06-21|
    JPS53126089A|1977-04-11|1978-11-02|Akiyama Jiyouzai Kk|Cyclodextrin clathrate compound including safflower oil|
    HU174699B|1977-07-01|1980-03-28|Chinoin Gyogyszer Es Vegyeszet|Process for preparing cyclodextrin inclusion complexes of natural and synthetic spices, aromatic and flavoring materials|HU184066B|1979-12-28|1984-06-28|Chinoin Gyogyszer Es Vegyeszet|Plant growth regulating substance and process for preparing such compound|
    JPS6241570B2|1980-07-16|1987-09-03|Wakunaga Seiyaku Kk|
    HU180183B|1980-12-19|1983-02-28|Chinoin Gyogyszer Es Vegyeszet|Process for preparing stable suppository compositions containing volatile and/or labile active substances|
    JPS5830032B2|1981-02-18|1983-06-27|Kureha Chemical Ind Co Ltd|
    JPS5813541A|1981-07-16|1983-01-26|Kureha Chem Ind Co Ltd|Cyclodextrin clathrate compound of eicosapentaenoic acid or docosahexaenoic acid|
    JPS5920230A|1982-07-19|1984-02-01|Ciba Geigy Ag|Drug containing piruprophen|
    GB2179551A|1984-09-01|1987-03-11|Jeanette Hill|Hair treatment preparations|
    FR2578422B1|1985-03-05|1987-06-26|Cariel Leon|TREATMENT COMPOSITION FOR EXTERNAL LUTEOLINE-BASED USE AND PREPARATION METHOD|
    HU196306B|1985-04-01|1988-11-28|Chinoin Gyogyszer Es Vegyeszet|New dusting powders comprising bioactive material and process for preparing the same|
    EP0211392B1|1985-08-06|1991-03-27|Kao Corporation|Liquid shampoo composition|
    DE68916430T2|1989-04-28|1994-10-13|Deryabin Alexandr Mikhailovic|PREPARATION OF MEDICINAL PRODUCTS FOR TREATING MASTITIS IN ANIMAL AND MAN.|
    DE4338508A1|1993-11-11|1995-05-18|Asta Medica Ag|Pharmaceutical preparations containing thioctic acid or dihydroliponic acid in the form of inclusion compounds with cyclodextrins or cyclodextrin derivatives and in the form of granules, chewable or effervescent tablets|
    CA2211222A1|1996-09-04|1998-03-04|Warner-Lambert Company|Shaving aid with complexing agent|
    DE19746284A1|1997-10-20|1999-04-22|Robugen Gmbh|Reducing odor of camomile extract or oil by cyclodextrin treatment, useful in pharmaceuticals and/or cosmetics having antiinflammatory activity|
    ES2171147B1|2001-02-06|2003-12-16|Esteve Labor Dr|PREPARATION FOR VETERINARY USES.|
    WO2004035071A1|2002-10-17|2004-04-29|Nakar, Herzl|Herbal medicine containing cyclodextrins for the treatment of ear disorders|
    FR2898817B1|2006-03-23|2008-08-08|Univ Rouen|ASSOCIATION OF OLEAGINOUS SUBSTANCE WITH A MIXTURE OF AT LEAST TWO CYCLODEXTRINS|
    JP2009091309A|2007-10-10|2009-04-30|Japan Organo Co Ltd|Composition containing bacopa monniera extract and its manufacturing method, as well as drinks and foods|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    HU78CI1867A|HU176217B|1978-11-20|1978-11-20|Process for preparing a cyclodextrin-chamomille inclusion complex and compositions containing thereof|
    [返回顶部]